Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ADC Therapeutics SA - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ADCT
New York
8731
https://adctherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ADC Therapeutics SA
Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why
- Jan 25th, 2023 3:21 pm
Amarin Corporation (AMRN) Down 13% in One Week: Here's Why
- Jan 23rd, 2023 4:01 pm
Wall Street Analysts Think ADC Therapeutics SA (ADCT) Could Surge 174.2%: Read This Before Placing a Bet
- Jan 16th, 2023 2:55 pm
ADC Therapeutics SA (ADCT) Stock Jumps 21.8%: Will It Continue to Soar?
- Jan 13th, 2023 12:28 pm
ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
- Jan 4th, 2023 12:15 pm
ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer
- Jan 3rd, 2023 9:30 pm
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Dec 21st, 2022 7:00 am
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
- Dec 19th, 2022 12:15 pm
FREENOME PRESENTS RESEARCH HIGHLIGHTING THE PROMISE OF IDENTIFYING DRUG-RESPONSE BIOMARKERS FOR DLBCL PATIENTS
- Dec 12th, 2022 1:00 pm
FDA Takes Tougher Line on Fast-Tracked Drugs
- Dec 5th, 2022 10:30 am
Biocytogen Enters into Antibody Agreement with ADC Therapeutics
- Nov 28th, 2022 2:47 pm
The past year for ADC Therapeutics (NYSE:ADCT) investors has not been profitable
- Nov 16th, 2022 12:05 pm
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates
- Nov 8th, 2022 1:15 pm
ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
- Nov 8th, 2022 12:00 pm
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
- Nov 7th, 2022 12:15 pm
Arcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains?
- Nov 4th, 2022 9:46 am
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting
- Nov 3rd, 2022 1:34 pm
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
- Nov 2nd, 2022 8:05 pm
ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer
- Nov 1st, 2022 11:15 am
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022
- Oct 31st, 2022 11:15 am
Scroll